NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
Clinical Trials
10 trialsNCT03747484 2025-03-06
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03853317 2024-08-09
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
Phase 2 Terminated
NCT02465957 2024-05-02
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
Phase 2 Terminated
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04590781 2023-04-20
DUET-1-02
Xencor, Inc.
Phase 1/2 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02584829 2022-03-22
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03988647 2021-08-09
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated